| pubmed-article:2907047 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2907047 | lifeskim:mentions | umls-concept:C0031785 | lld:lifeskim |
| pubmed-article:2907047 | lifeskim:mentions | umls-concept:C0040615 | lld:lifeskim |
| pubmed-article:2907047 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:2907047 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:2907047 | pubmed:dateCreated | 1989-5-11 | lld:pubmed |
| pubmed-article:2907047 | pubmed:abstractText | A series of N-(4-phenyl- and 4-pyridyl-1-piperazinylethyl)- and N-(4-phenyl-1-piperidinylethyl)-phthalmides were synthesized and tested for antipsychotic activity. All compounds suppressed the spontaneous motor activity and the apomorphine-induced climbing in mice and pergolide-induced locomotor activity in rats, demonstrating psychotropic properties equal to the corresponding properties of sulpiride. Although the compounds, like sulpiride, were less potent than haloperidol in blocking the locomotor activities, they caused no catalepsy, a major side effect following treatment with conventional antipsychotic agents. It is likely that the new compounds produce their neuroleptic activities through inhibition of limbic dopamine receptors. | lld:pubmed |
| pubmed-article:2907047 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2907047 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2907047 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2907047 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2907047 | pubmed:issn | 0022-3549 | lld:pubmed |
| pubmed-article:2907047 | pubmed:author | pubmed-author:MustafaA AAA | lld:pubmed |
| pubmed-article:2907047 | pubmed:author | pubmed-author:AlhaiderA AAA | lld:pubmed |
| pubmed-article:2907047 | pubmed:author | pubmed-author:GinawiO TOT | lld:pubmed |
| pubmed-article:2907047 | pubmed:author | pubmed-author:el-ObeidH AHA | lld:pubmed |
| pubmed-article:2907047 | pubmed:author | pubmed-author:al-RashoodK... | lld:pubmed |
| pubmed-article:2907047 | pubmed:author | pubmed-author:MadaniA AAA | lld:pubmed |
| pubmed-article:2907047 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2907047 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:2907047 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2907047 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2907047 | pubmed:pagination | 898-901 | lld:pubmed |
| pubmed-article:2907047 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:meshHeading | pubmed-meshheading:2907047-... | lld:pubmed |
| pubmed-article:2907047 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2907047 | pubmed:articleTitle | Antipsychotic properties of new N-(4-substituted-1-piperazinylethyl)- and N-(4-substituted-1-piperidinylethyl)-phthalimides. | lld:pubmed |
| pubmed-article:2907047 | pubmed:affiliation | College of Pharmacy, Department of Pharmaceutical Chemistry, King Saud University, Riyadh, Saudi Arabia. | lld:pubmed |
| pubmed-article:2907047 | pubmed:publicationType | Journal Article | lld:pubmed |
